...
首页> 外文期刊>The journal of gene medicine >5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16~(INK4A) greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells
【24h】

5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16~(INK4A) greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells

机译:5-氟尿嘧啶或吉西他滨联合腺病毒介导的p16〜(INK4A)的重新引入大大增强了Panc-1胰腺腺癌细胞的细胞毒性

获取原文
获取原文并翻译 | 示例
           

摘要

Background Pancreatic cancer is one of the most lethal of all the common gastrointestinal malignancies. Although surgery offers the best chance for survival, it is not appropriate for all cases. The only adjuvant treatment to show promise is chemotherapy. Hence new treatments are urgently sought. We previously reported that adenoviral (Ad)-mediated delivery of p53 (Adp53) and p16~(INK4A) (Adp16) significantly inhibited the growth of pancreatic cancer cell lines and established subcutaneous pancreatic tumours in nude mice (Ghaneh P, et al. Adenovirus mediated transfer of p53 and p16~(INK4A) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8: 199-208). In this study we examine whether combining Ad-mediated delivery of p53 or p16~(INK4A) with clinically relevant chemotherapeutic drugs has therapeutic potential for pancreatic cancer. Methods and results Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine. We found no evidence for enhanced cytotoxicity when either cell line was transduced with Adp53 before or after incubation with chemotherapeutic drugs. In contrast, incubation of Panc-1 cells with either 5-FU or gemcitabine followed by Ad-mediated overexpression of p16~(INK4A) resulted in a substantial reduction in cell viability under conditions where the drugs alone had minimal cytotoxicity. Incubation of Suit-2 cells with 5-FU followed by Ad-mediated overexpression of p16~(INK4A) also resulted in a significant reduction in cell viability. This, however, was observed only with higher concentrations of 5-FU and viral vector. Cell cycle analysis of Panc-1 cells showed that the combination of cytotoxic drugs and Adp16 resulted in an increase in the sub-G1 population suggesting an increase in apoptosis. Dual labelling of these cells with annexin V and propidium iodide (PI) confirmed that the combination of 5-FU and Adp16 resulted in a significant increase in early apoptotic cells (annexin V positive and PI negative) compared with controls. Moreover, overexpression of p16~(INK4A) was associated with a reduction in pRb levels in these cells-high levels of pRb have been proposed to contribute to chemoresistance in pancreatic cancer cells. Conclusions We have shown that the currently used chemotherapeutic drugs for pancreatic adenocarcinoma combined with restoration of p16~(INK4A) expression hold promise for the adjuvant treatment of this disease. Importantly, the combination facilitated the use of chemotherapeutic drugs at lower concentrations than would otherwise be effective.
机译:背景胰腺癌是所有常见胃肠道恶性肿瘤中最致命的疾病之一。尽管手术提供了最佳的生存机会,但并不适合所有情况。唯一有希望的辅助治疗是化疗。因此,迫切需要新的治疗方法。我们之前曾报道过腺病毒(Ad)介导的p53(Adp53)和p16〜(INK4A)(Adp16)的递送显着抑制了胰腺癌细胞系的生长并在裸鼠中建立了皮下胰腺肿瘤(Ghaneh P,et al.Adenovirus p53和p16〜(INK4A)介导的转移导致胰腺癌在体内和体外消退(Gene Ther 2001; 8:199-208)。在这项研究中,我们研究了将Ad介导的p53或p16〜(INK4A)与临床相关的化学治疗药物联合使用是否具有治疗胰腺癌的潜力。方法和结果评估了4种胰腺腺癌细胞对5-氟尿嘧啶(5-FU)和吉西他滨的敏感性,并选择其中2种(Suite-2和Panc-1)进行组合实验,因为它们显示出中度和较差的敏感性,分别为5-FU和吉西他滨。我们发现,在与化疗药物孵育之前或之后,用Adp53转导任一细胞系均未发现增强细胞毒性的证据。相比之下,将Panc-1细胞与5-FU或吉西他滨孵育,然后Ad介导的p16〜(INK4A)过表达会导致在单独药物具有最小细胞毒性的条件下细胞活力的显着降低。 Suit-2细胞与5-FU孵育后,Ad介导的p16〜(INK4A)过表达也导致细胞活力显着降低。但是,只有在较高浓度的5-FU和病毒载体中才能观察到这一点。 Panc-1细胞的细胞周期分析表明,细胞毒性药物和Adp16的组合导致sub-G1群体增加,提示凋亡增加。用膜联蛋白V和碘化丙啶(PI)对这些细胞进行双重标记证实,与对照组相比,5-FU和Adp16的组合可导致早期凋亡细胞(annexin V阳性和PI阴性)显着增加。此外,p16〜(INK4A)的过表达与这些细胞中pRb水平的降低有关,有人提出高水平的pRb有助于胰腺癌细胞的化学耐药性。结论我们已经表明,目前用于胰腺癌的化学治疗药物与p16〜(INK4A)表达的恢复相结合有望为该疾病的辅助治疗提供希望。重要的是,该组合促进了以比本来有效的浓度更低的浓度使用化学治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号